Fractyl Health, Inc.
An American medical company treating obesity and type 2 diabetes at their root. Its lead procedure, Revita, uses a heat-based endoscopic device to resurface the lining of the small intestine, helping people keep weight off after stopping GLP-1 drugs; its Rejuva platform delivers genes that reprogram insulin-making pancreatic cells. Founded in 2010 as MedCatalyst, the firm took its name from "fractal," echoing the repeating folds inside the intestine, and trades on Nasdaq as "GUTS."
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 13G/APassive | 9.99% | 16.12M | May 15, 2026 |
| Wilmot B. Harkey | 13G/APassive | 9.99% | 16.12M | May 15, 2026 |
| Daniel Mack | 13G/APassive | 9.99% | 16.12M | May 15, 2026 |
| 683 Capital Management, LLC | 13G/APassive | 4.81% | 7.68M | May 15, 2026 |
| 683 Capital Partners, LP | 13G/APassive | 4.81% | 7.68M | May 15, 2026 |
| Ari Zweiman | 13G/APassive | 4.81% | 7.68M | May 15, 2026 |
| SilverArc Capital Management, LLC | 13G/APassive | 2.3% | 3.61M | May 13, 2026 |
| Devesh Gandhi | 13G/APassive | 2.3% | 3.61M | May 13, 2026 |
| Alyeska Investment Group, L.P. | 13G/APassive | 4.97% | 7.62M | Feb 17, 2026 |
| Alyeska Fund GP, LLC | 13G/APassive | 4.97% | 7.62M | Feb 17, 2026 |